FDA and UK regulators discuss new frameworks for generative AI oversight

At the MedTech Conference in Boston, officials from the U.S. Food and Drug Administration and the U.K. Medicines and Healthcare products Regulatory Agency met to talk about how to regulate generative artificial intelligence products.

The two agencies said they are working on regulatory approaches that reflect the unique characteristics of genAI, aiming for frameworks that are more flexible and better aligned with rapid technological change.

Both regulators indicated that a coordinated, streamlined system could help ensure safety while fostering innovation in the emerging genAI market.